NEWS September 28, 2017

Immune’s rare skin disease drug maintains shine

Story in BioWorld by Michael Fitzhugh. Preliminary data on three additional patients enrolled in a small open-label study of Immune Pharmaceuticals Inc.’s bertilimumab, an experimental treatment for the rare blistering disease bullous pemphigoid (BP), continued to suggest it may offer an effective alternative to systemic corticosteroids, a standard but imperfect therapy for the condition. Immune, which is seeking an […]

Keep Reading

NEWS May 5, 2016

Delving Deep into Immune Pharmaceuticals’ Diverse Pipeline

Immune Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focusing on the treatment of immuno-inflammatory diseases and cancer. The company has several active clinical programs, led by bertilimumab, a first-in-class, fully human IgG4 monoclonal antibody, which is currently in Phase 2 clinical trials for the treatment of inflammatory bowel disease and skin disorders. Immune Pharma also […]

Keep Reading

NEWS April 21, 2016

Immune Presents Biomarker Data On Ceplene at AACR

A team of researchers from Gothenburg University in Sweden presented data from a Phase 4 study on Ceplene® earlier this week at the American Association for Cancer Research (AACR) Annual Meeting in New Orleans, LA. These data could have a profound impact on future use of the drug in elderly patients with Acute Myeloid Leukemia (AML). […]

Keep Reading

NEWS April 7, 2016

Can Immune Pharma Compete with Regeneron and Anacor Blockbuster Drugs for Eczema?

Ari Zoldan | Thursday, 07 April 2016 17:08 (EST) Immune Pharmaceuticals is competing with industry giants Regeneron and Sanofi and mid-cap company Anacor Pharmaceuticals, in an attempt to cure eczema. The micro-stock and its competitors are in the process of developing drugs for atopic dermatitis (AD), the most common form of chronic eczema. According to Dr. Neil Korman, […]

Keep Reading